<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02209779</url>
  </required_header>
  <id_info>
    <org_study_id>1175.11</org_study_id>
    <nct_id>NCT02209779</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Different Doses of BIRB 796 BS in Patients With Active Rheumatoid Arthritis</brief_title>
  <official_title>A Randomised, Parallel, Double-blind, Placebo-controlled Study to Investigate Efficacy and Safety of Different Doses (5, 10, 20 and 30 mg) of BIRB 796 BS Administered Twice a Day Orally Over 4 Weeks in Patients With Active Rheumatoid Arthritis Who Have Failed at Least One DMARD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective was to determine the effects of BIRB 796 BS on CRP and clinical parameters in&#xD;
      Rheumatoid Arthritis as measures of efficacy, and on population pharmacokinetics and safety&#xD;
      parameters&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <primary_completion_date type="Actual">June 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute difference to baseline in concentrations of C-reactive Protein (CRP)</measure>
    <time_frame>before and after 4 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute difference to baseline in tender joint count (TJC, 68 joint count)</measure>
    <time_frame>before and after 4 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute difference to baseline in swollen joint count (SJC, 66 joint count)</measure>
    <time_frame>before and after 4 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients assessment of pain on a visual analogue scale (VAS)</measure>
    <time_frame>up to 57 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients global assessment of disease activity (PADA) on a VAS</measure>
    <time_frame>up to 57 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physicians global assessment of disease activity on a VAS</measure>
    <time_frame>up to 57 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of physical function by a standardised health assessment questionnaire (HAQ)</measure>
    <time_frame>up to 57 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute difference to baseline in Erythrocyte sedimentation rate (ESR)</measure>
    <time_frame>up to 57 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute difference to baseline in Cytokines Tumor Necrosis Factor (TNF)-α, soluble TNF-Receptor (sTNF-R), Interleukin (IL)-1ra, IL-6</measure>
    <time_frame>Day 1, 8 and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute difference to baseline in Matrix metalloprotease-3 (MMP-3)</measure>
    <time_frame>Day 1, 8 and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute difference to baseline in Vascular endothelial growth factor (VEGF)</measure>
    <time_frame>Day 1, 8 and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of responders to American College of Rheumatology (ACR) preliminary response criteria for 20% improvement (ACR 20), ACR 50, ACR 70</measure>
    <time_frame>after 4 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of responders to European League against Rheumatism (EULAR) response criteria</measure>
    <time_frame>after 4 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of drop-outs due to lack of efficacy, according to final assessment of investigator</measure>
    <time_frame>after 4 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of maximum concentration (Cmax)</measure>
    <time_frame>Day 15, 22, 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of area under the curve (AUC) at steady state</measure>
    <time_frame>Day 15, 22, 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Adverse events</measure>
    <time_frame>up to day 73</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">167</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>BIBR 796 BS, low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>twice daily doses of 5 mg for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBR 796 BS, medium dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>twice daily doses of 10 mg for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBR 796 BS, medium dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>twice daily doses of 20 mg for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBR 796 BS, high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>twice daily doses of 30 mg for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 796 BS</intervention_name>
    <arm_group_label>BIBR 796 BS, high dose</arm_group_label>
    <arm_group_label>BIBR 796 BS, low dose</arm_group_label>
    <arm_group_label>BIBR 796 BS, medium dose 1</arm_group_label>
    <arm_group_label>BIBR 796 BS, medium dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>BIBR 796 BS, low dose</arm_group_label>
    <arm_group_label>BIBR 796 BS, medium dose 1</arm_group_label>
    <arm_group_label>BIBR 796 BS, medium dose 2</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female from 18 to 75 years of age&#xD;
&#xD;
          -  Diagnosis of Rheumatoid Arthritis (RA) established according to ACR criteria and date&#xD;
             of diagnosis &gt;1 year to ≤ 15 years. The exclusion of patients with a disease duration&#xD;
             &gt; 15 years was deleted in Amendment 2, effective January 22, 2002&#xD;
&#xD;
          -  Patient belonging to functional class I, II, or III&#xD;
&#xD;
          -  Failure of at least one Disease Modifying Antirheumatic Drug (DMARD) due to inefficacy&#xD;
&#xD;
          -  Active disease, documented at visit 3, defined by ≥10 swollen joints in a 66 joint&#xD;
             count and ≥ 12 tender joints in a 68 joint count&#xD;
&#xD;
          -  CRP ≥ 2.0 mg/dl at visit 1 or visit 2&#xD;
&#xD;
          -  Written informed consent in accordance with Good Clinical Practice and local&#xD;
             legislation given prior to any study procedures, including washout of prohibited&#xD;
             medications&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy (to be excluded by serum and urine β Human Chorion-Gonadotropin-test in&#xD;
             women of childbearing potential) or breast feeding&#xD;
&#xD;
          -  Female of childbearing potential (not 6 months post-menopausal or surgically&#xD;
             sterilized) not using an approved form of birth control (hormonal contraceptives, oral&#xD;
             or injectable/implantable, intra-uterine device (IUD))&#xD;
&#xD;
          -  Inflammatory rheumatic disease other than RA&#xD;
&#xD;
          -  Active vasculitis or any history of vasculitis (characterised by e.g. nail bed&#xD;
             hemorrhages or infarcts, vasculitic purpura, ulcers or gangrenes, multisensory&#xD;
             neuropathy, vasculitic retinopathy or scleritis of eyes). Isolated rheumatoid nodules&#xD;
             of the skin are not a criterion for exclusion&#xD;
&#xD;
          -  Treatment failure to a TNF-blocking agent. Treatment failure is defined as not&#xD;
             achieving at least an ACR 20 response (e.g. in a clinical trial) or - in clinical&#xD;
             practice - having the TNF-blocking agent discontinued due to ineffectiveness&#xD;
&#xD;
          -  DMARD treatment within 4 weeks before visit 3&#xD;
&#xD;
          -  Last dose given within the specified time period before visit 3 for one of the&#xD;
             following compounds or drugs:&#xD;
&#xD;
               -  Infliximab (Remicade®): 3 months&#xD;
&#xD;
               -  D2E7 (a human TNF-α antibody): 3 months&#xD;
&#xD;
               -  Leflunomide (Arava®): 1 year, with exception of patients having undergone&#xD;
                  elimination therapy (colestyramin 8 grams t.i.d. po for eleven consecutive days),&#xD;
                  this exclusion criterion was deleted in Amendment 1, effective September 3, 2001&#xD;
&#xD;
               -  Drug classified as proton pump inhibitor: 7 days&#xD;
&#xD;
               -  Drug classified as H2-receptor-blocker or antacid: 2 days&#xD;
&#xD;
               -  Investigational agent: 5-fold of the respective plasma half life or 4 weeks,&#xD;
                  whichever is longer&#xD;
&#xD;
          -  Treatment with systemic corticosteroids in a dose higher than 10 mg/day prednisone&#xD;
             equivalent within 4 weeks prior to visit 3&#xD;
&#xD;
          -  Change in treatment with nonsteroidal antiinflammatory drugs (NSAIDs) or systemic&#xD;
             corticosteroids within 4 weeks prior to visit 3&#xD;
&#xD;
          -  Synovectomy, joint surgery, radio-/chemo synoviorthesis or steroid injections&#xD;
             (intraarticular, intravenous or intramuscular) within 4 weeks before visit 3&#xD;
&#xD;
          -  Active infection or serious infectious diseases resulting in hospitalisation or&#xD;
             requiring systemic anti-infective therapy within 4 weeks before visit 3&#xD;
&#xD;
          -  Serologic evidence of active hepatitis B and/or C&#xD;
&#xD;
          -  Known HIV-infection&#xD;
&#xD;
          -  History of prior tuberculosis infection or suspicion of active infection at screening&#xD;
             based on chest x-ray done within 6 month before visit 1&#xD;
&#xD;
          -  History of cardiovascular, renal, neurologic, psychiatric, liver, gastrointestinal,&#xD;
             immunologic or endocrine dysfunction if they are clinically significant. A clinically&#xD;
             significant disease is defined as one which in the opinion of the investigator may&#xD;
             either put the patient at risk because of participation in the study or a disease&#xD;
             which may influence the results of the study or the patient's ability to participate&#xD;
             in the study&#xD;
&#xD;
          -  Recent history of heart failure, defined according to New York Heart Association&#xD;
             criteria as being stage III or IV (i.e. three years or less) or myocardial infarction&#xD;
             (i.e. one year or less) or patients with any cardiac arrhythmia requiring drug&#xD;
             therapy. This exclusion criterion was slightly modified in Amendment 2, effective&#xD;
             January 22, 2002.&#xD;
&#xD;
          -  ECG results outside of the reference range of clinical relevance including, but not&#xD;
             limited to QTcB &gt; 480 msec, PR interval &gt; 240 msec, QRS interval &gt; 110 msec&#xD;
&#xD;
          -  History of malignant disease in the last 5 years or suspicion of active malignant&#xD;
             disease except successfully treated squamous or basal cell carcinoma of the skin&#xD;
&#xD;
          -  Clinically significant abnormal baseline hematology, blood chemistry or urinalysis if&#xD;
             the abnormality defines a disease listed as an exclusion criterion&#xD;
&#xD;
          -  Any of the following specific laboratory abnormalities:&#xD;
&#xD;
               -  Alanine aminotransferase, aspartate aminotransferase, or total bilirubin greater&#xD;
                  than upper limit of normal (ULN) at visit 1 or measured within the last six&#xD;
                  months before visit 3. This exclusion criterion was modified in Amendment 1,&#xD;
                  effective September 3, 2001, allowing for a retest at Visit 2.&#xD;
&#xD;
               -  Gamma-Glutamyltransferase, alkaline phosphatase or Lactate Dehydrogenase greater&#xD;
                  than 1.5 x ULN at visit 1&#xD;
&#xD;
               -  creatinine or white blood cell count greater than 1.5 x ULN at visit 1&#xD;
&#xD;
          -  History of drug or alcohol abuse within the past two years or active drug or alcohol&#xD;
             abuse, present alcohol intake more than three drinks per day&#xD;
&#xD;
          -  Inability to comply with the protocol&#xD;
&#xD;
          -  Participation in another clinical trial within 30 days before visit 3&#xD;
&#xD;
          -  Previous enrolment in this trial&#xD;
&#xD;
          -  Hypersensitivity to trial drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>August 5, 2014</study_first_submitted>
  <study_first_submitted_qc>August 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2014</study_first_posted>
  <last_update_submitted>August 5, 2014</last_update_submitted>
  <last_update_submitted_qc>August 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

